Inactivated Vaccines Market Share, Size, Trends, and Forecast by 2031

Coverage: Inactivated Vaccines Market covers analysis by Type ( Viral Vaccine, Bacterial Vaccine ); Method ( Solvent Detergent Method, Radiation Method, pH Concentration, Heat Inactivation, Others ); Route of Administration ( Oral, Subcutaneous, Intravenous, Others ), and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00010958
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

The Inactivated Vaccines Market is expected to register a CAGR of 3.95% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.

The report is segmented by Type (Viral Vaccine, Bacterial Vaccine); Method (Solvent Detergent Method, Radiation Method, pH Concentration, Heat Inactivation, Others); and Route of Administration (Oral, Subcutaneous, Intravenous, Others). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.

Purpose of the Report

The report Inactivated Vaccines Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  • Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  • Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  • Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Inactivated Vaccines Market Segmentation

Type
  • Viral Vaccine
  • Bacterial Vaccine
Method
  • Solvent Detergent Method
  • Radiation Method
  • pH Concentration
  • Heat Inactivation
Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous

Strategic Insights

Inactivated Vaccines Market Growth Drivers
  • Rising Incidence of Infectious Diseases: The increasing prevalence of infectious diseases is a significant growth driver in the inactivated vaccine market. The market for inactivated vaccines grows because infectious diseases spread more often. Healthcare systems worldwide and their governments allocate substantial funds to vaccination programs because infectious diseases like influenza, polio, and hepatitis still affect many people globally. Inactivated vaccines protect people effectively while maintaining a good safety record to prevent and control infectious diseases. Developed and emerging nations boost their vaccination programs when disease outbreaks rise which creates more demand for inactivated vaccines. The Global Vaccine Safety Initiative and GAVI Alliance work globally to expand vaccination programs which will expand the market size. People who have weakened immune systems prefer inactivated vaccines because they lack living microorganisms that could harm them. More people are choosing inactivated vaccines because they want safer protection and are learning about vaccination more. The appearance of new viral diseases including COVID-19 shows healthcare needs require better vaccine solutions which will drive industry growth. The market for inactivated vaccines will expand steadily because governments are investing more in public health programs and increasing vaccine distribution.
  • Advancements in Vaccine Development Technology: Technological progress in vaccine manufacturing and research fuels market expansion for inactivated vaccines. Scientists develop better inactivated vaccines using recombinant DNA methods plus new formulation techniques with added adjuvants. Pharmaceutical companies can now produce better vaccines that save money and reach more people through advanced technology. Modern vaccine production methods help inactivated vaccines reach more people safely with lower disease risk. Vaccine production technologies such as cell-culture and fermentation enable manufacturers to create more vaccine at lower prices which makes the treatment available to more people. New types of adjuvants help vaccine formulas work better for inactivated vaccines. Vaccine manufacturers use advanced technology to make more vaccines while spending less which increases the size of the global inactivated vaccines market. The market grows faster when vaccine makers can produce more vaccines faster to fight disease outbreaks. Market projections show vaccine market expansion because companies develop better vaccines through improved production methods.
  • Increasing Government Initiatives and Vaccination Campaigns: Governments and international groups now focus more on vaccine programs especially in developing nations with higher disease rates. Public health services that provide vaccines to everyone and focus on high-risk groups help spread the use of inactivated vaccines worldwide. Through the WHO's Expanded Programme on Immunization and other vaccination programs the organization works to boost worldwide vaccine administration which will create more demand for inactivated vaccines. Governments invest in healthcare infrastructure to bring vaccines closer to people in remote areas while backing big-scale vaccination programs with funds. National healthcare programs that require inactivated vaccines for influenza polio and hepatitis B boost market growth. More governments are investing in vaccines because they understand vaccines help prevent diseases so the market for inactivated vaccines is trending up. The worldwide market for inactivated vaccines will expand as healthcare systems develop and more people get access to vaccines according to projected trends. The global inactivated vaccines market will keep growing because vaccination efforts are expanding worldwide.
Inactivated Vaccines Market Future Trends
  • Expansion of Seasonal Vaccination Programs: Many healthcare facilities now run seasonal vaccine programs including influenza shots for the inactivated vaccine sector. The public health system wants to give more people inactivated flu vaccines because seasonal flu threatens everyone's health in the community. World health professionals and government agencies tell everyone to receive yearly flu shots every year which increases demand for inactivated vaccines. The seasonal vaccination programs reach more people because the new vaccines fight different influenza virus types better. The COVID-19 pandemic taught us that seasonal vaccines protect us effectively and people now know better how inactivated vaccines prevent viral infections. People will get flu vaccines every season more often which means more revenue for inactivated vaccine manufacturers. The market expects more people to get vaccinated through public health programs as these organizations work to create new flu vaccines to protect against different virus strains. This global market for inactivated vaccines will expand rapidly because of this trend.
  • Integration of Inactivated Vaccines in Global Health Programs: Health organizations worldwide now prefer to use inactivated vaccines for their programs in developing countries. Inactivated vaccines need to increase for immunization programs because low-income nations experience growing outbreaks of polio and hepatitis infections. The GAVI Alliance and Global Polio Eradication Initiative (GPEI) run worldwide programs to deliver vaccines to poor nations. These programs enable better vaccine supply to countries with few resources and open new potential markets for inactivated vaccines. As these programs grow they will need more inactivated vaccines to serve their expanded populations which will grow the vaccine industry. The regions will use more inactivated vaccines because people find them simpler to access plus there are updated methods to administer them. Health organizations everywhere want to stop preventable diseases by using inactivated vaccines which research shows will grow their market value.
  • Personalized Vaccination Strategies: Personalized medicine is the latest addition to the inactivated vaccines industry. Healthcare providers create one-of-a-kind vaccination schedules that fit the unique genetic and medical data of each patient. The vaccine industry creates special vaccines to shield specific groups such as elderly people and patients who have weak immune systems or manage chronic medical conditions. Using vaccines that match patient needs makes them safer and more effective at stopping disease plus patients follow their drug regimens better. Inactivated vaccines stand out as the best option for personalized treatments because they have shown reliable safety data already. Research into immune profiles and genes will help us develop vaccines that match patients better which will drive up demand for inactivated vaccines. Specialized vaccines will help the inactivated vaccine market grow as experts say it will capture more customers.
Inactivated Vaccines Market Opportunities
  • Vaccine Portfolio Expansion through New Indications: An important growth opportunity for the inactivated vaccines market lies in the expansion of vaccine portfolios to include new indications. The inactivated vaccines market will grow when producers add new disease types to their vaccine lines. People already use inactivated vaccines against influenza polio and hepatitis but scientists study them for more infectious diseases. Scientists develop inactivated vaccines to fight dengue fever and malaria plus newly discovered viruses including Zika and COVID-19. This growth strategy creates fresh revenue sources for vaccine companies due to rising demand in these areas. The quick development of COVID-19 vaccines including inactivated designs has made the market more prominent and gave it a larger market share. The market will grow bigger because research shows that inactivated vaccines work well against new diseases plus more people worldwide want vaccines. The market for inactivated vaccines will expand due to increased prevention efforts by public health agencies and national authorities. The market has more opportunities because researchers can use existing inactivated vaccines to treat different medical needs. Manufacturers will expand vaccine production while finding new applications for this vaccine technology to push market growth higher. Consumers and pharmaceutical companies believe new vaccine discoveries will grow market value by expanding both share and size while treating unmet health needs.
  • Rising Demand for Travel Vaccines: The rise in international travel creates new demand for travel vaccines which makes the inactivated vaccines market an attractive opportunity. People need travel-related vaccines like yellow fever, typhoid, and hepatitis A because these diseases are common in specific travel destinations. People usually get these vaccines because they protect against disease without serious side effects. More international travelers for tourism business and education will lead to increased demand for inactivated vaccines which will grow this market segment. Health authorities and governments make it mandatory for travelers to show proof of vaccination before entering disease-endemic areas which pushes up demand even more. Travelers now have more choices of inactivated vaccines that protect against multiple diseases which expands the market's potential. New methods for vaccine administration such as simple injections and oral medications help more people access vaccines. People understand travel-related disease risks better which means more people will need inactivated vaccines in the future. Market experts predict travel-related inactivated vaccine sales will keep growing because people are more mobile and prioritize health prevention worldwide. Vaccine companies can strengthen their market position in global inactivated vaccines through targeted product development that matches traveler requirements.
  • Increasing Focus on Vaccination in Aging Populations: The rising senior population worldwide offers market expansion chances to inactivated vaccine companies. Healthcare providers recognize the growing elderly population worldwide by developing vaccines that better serve older adults. Older adults face higher risk of getting influenza pneumonia and shingles so vaccines help them stay healthy longer. The elderly population benefits from inactivated vaccines because they have a better safety record than other vaccines. Healthcare providers and government agencies work to boost vaccination rates among older adults which will boost market expansion. Many nations have started adding vaccines against influenza pneumococcal and shingles infections to their immunization programs because these diseases affect older adults more often. Healthcare providers see the value of preventive vaccines for seniors and expect growing demand in this market segment. When older people choose vaccines to defend against age-related illnesses the market for inactivated vaccines will develop substantially. The inactivated vaccines market will expand because market experts expect more elderly people to need vaccinations as part of their healthy aging plans. Vaccine producers see a clear market opportunity to grow their business by creating vaccines that serve older adults specifically.

Market Report Scope

Key Selling Points

  • Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Inactivated Vaccines Market, providing a holistic landscape.
  • Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  • Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  • Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Inactivated Vaccines Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.

REGIONAL FRAMEWORK
World Geography

Have a question?

Analyst

Mrinal

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst   Speak to Analyst
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
MARKET PLAYERS
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the expected CAGR of the Inactivated Vaccines Market?

The Inactivated Vaccines Market is estimated to witness a CAGR of 3.95% from 2025 to 2031.

What are the driving factors impacting the Inactivated Vaccines Market?

The major factors driving the Inactivated Vaccines Market are the Rising Incidence of Infectious Diseases, Advances in Vaccine Development Technology, and Increasing Government Initiatives and Vaccination Campaigns.

What are the future trends of the Inactivated Vaccines Market?

Future trends in the Inactivated Vaccines Market are Expansion of Seasonal Vaccination Programs, Integration of Inactivated Vaccines in Global Health Programs, and Personalized Vaccination Strategies.

Which are the leading players in the Inactivated Vaccines Market?

Some of the players operating in the market are Bharat Biotech, CSL Ltd., Emergent BioSolutions, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Seqirus, Valneva SE.

What are the deliverable formats of the Inactivated Vaccines Market report?

The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.

What are the options available for the customization of this report?

Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Inactivated Vaccines Market - By Type
1.3.2 Inactivated Vaccines Market - By Method
1.3.3 Inactivated Vaccines Market - By Route of Administration
1.3.4 Inactivated Vaccines Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. INACTIVATED VACCINES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. INACTIVATED VACCINES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. INACTIVATED VACCINES MARKET - GLOBAL MARKET ANALYSIS
6.1. INACTIVATED VACCINES - GLOBAL MARKET OVERVIEW
6.2. INACTIVATED VACCINES - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. INACTIVATED VACCINES MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. VIRAL VACCINE
7.3.1. Overview
7.3.2. Viral Vaccine Market Forecast and Analysis
7.4. BACTERIAL VACCINE
7.4.1. Overview
7.4.2. Bacterial Vaccine Market Forecast and Analysis
8. INACTIVATED VACCINES MARKET - REVENUE AND FORECASTS TO 2028 - METHOD
8.1. OVERVIEW
8.2. METHOD MARKET FORECASTS AND ANALYSIS
8.3. SOLVENT DETERGENT METHOD
8.3.1. Overview
8.3.2. Solvent Detergent Method Market Forecast and Analysis
8.4. RADIATION METHOD
8.4.1. Overview
8.4.2. Radiation Method Market Forecast and Analysis
8.5. PH CONCENTRATION
8.5.1. Overview
8.5.2. pH Concentration Market Forecast and Analysis
8.6. HEAT INACTIVATION
8.6.1. Overview
8.6.2. Heat Inactivation Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. INACTIVATED VACCINES MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. ORAL
9.3.1. Overview
9.3.2. Oral Market Forecast and Analysis
9.4. SUBCUTANEOUS
9.4.1. Overview
9.4.2. Subcutaneous Market Forecast and Analysis
9.5. INTRAVENOUS
9.5.1. Overview
9.5.2. Intravenous Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. INACTIVATED VACCINES MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Inactivated Vaccines Market Overview
10.1.2 North America Inactivated Vaccines Market Forecasts and Analysis
10.1.3 North America Inactivated Vaccines Market Forecasts and Analysis - By Type
10.1.4 North America Inactivated Vaccines Market Forecasts and Analysis - By Method
10.1.5 North America Inactivated Vaccines Market Forecasts and Analysis - By Route of Administration
10.1.6 North America Inactivated Vaccines Market Forecasts and Analysis - By Countries
10.1.6.1 United States Inactivated Vaccines Market
10.1.6.1.1 United States Inactivated Vaccines Market by Type
10.1.6.1.2 United States Inactivated Vaccines Market by Method
10.1.6.1.3 United States Inactivated Vaccines Market by Route of Administration
10.1.6.2 Canada Inactivated Vaccines Market
10.1.6.2.1 Canada Inactivated Vaccines Market by Type
10.1.6.2.2 Canada Inactivated Vaccines Market by Method
10.1.6.2.3 Canada Inactivated Vaccines Market by Route of Administration
10.1.6.3 Mexico Inactivated Vaccines Market
10.1.6.3.1 Mexico Inactivated Vaccines Market by Type
10.1.6.3.2 Mexico Inactivated Vaccines Market by Method
10.1.6.3.3 Mexico Inactivated Vaccines Market by Route of Administration
10.2. EUROPE
10.2.1 Europe Inactivated Vaccines Market Overview
10.2.2 Europe Inactivated Vaccines Market Forecasts and Analysis
10.2.3 Europe Inactivated Vaccines Market Forecasts and Analysis - By Type
10.2.4 Europe Inactivated Vaccines Market Forecasts and Analysis - By Method
10.2.5 Europe Inactivated Vaccines Market Forecasts and Analysis - By Route of Administration
10.2.6 Europe Inactivated Vaccines Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Inactivated Vaccines Market
10.2.6.1.1 Germany Inactivated Vaccines Market by Type
10.2.6.1.2 Germany Inactivated Vaccines Market by Method
10.2.6.1.3 Germany Inactivated Vaccines Market by Route of Administration
10.2.6.2 France Inactivated Vaccines Market
10.2.6.2.1 France Inactivated Vaccines Market by Type
10.2.6.2.2 France Inactivated Vaccines Market by Method
10.2.6.2.3 France Inactivated Vaccines Market by Route of Administration
10.2.6.3 Italy Inactivated Vaccines Market
10.2.6.3.1 Italy Inactivated Vaccines Market by Type
10.2.6.3.2 Italy Inactivated Vaccines Market by Method
10.2.6.3.3 Italy Inactivated Vaccines Market by Route of Administration
10.2.6.4 Spain Inactivated Vaccines Market
10.2.6.4.1 Spain Inactivated Vaccines Market by Type
10.2.6.4.2 Spain Inactivated Vaccines Market by Method
10.2.6.4.3 Spain Inactivated Vaccines Market by Route of Administration
10.2.6.5 United Kingdom Inactivated Vaccines Market
10.2.6.5.1 United Kingdom Inactivated Vaccines Market by Type
10.2.6.5.2 United Kingdom Inactivated Vaccines Market by Method
10.2.6.5.3 United Kingdom Inactivated Vaccines Market by Route of Administration
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Inactivated Vaccines Market Overview
10.3.2 Asia-Pacific Inactivated Vaccines Market Forecasts and Analysis
10.3.3 Asia-Pacific Inactivated Vaccines Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Inactivated Vaccines Market Forecasts and Analysis - By Method
10.3.5 Asia-Pacific Inactivated Vaccines Market Forecasts and Analysis - By Route of Administration
10.3.6 Asia-Pacific Inactivated Vaccines Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Inactivated Vaccines Market
10.3.6.1.1 Australia Inactivated Vaccines Market by Type
10.3.6.1.2 Australia Inactivated Vaccines Market by Method
10.3.6.1.3 Australia Inactivated Vaccines Market by Route of Administration
10.3.6.2 China Inactivated Vaccines Market
10.3.6.2.1 China Inactivated Vaccines Market by Type
10.3.6.2.2 China Inactivated Vaccines Market by Method
10.3.6.2.3 China Inactivated Vaccines Market by Route of Administration
10.3.6.3 India Inactivated Vaccines Market
10.3.6.3.1 India Inactivated Vaccines Market by Type
10.3.6.3.2 India Inactivated Vaccines Market by Method
10.3.6.3.3 India Inactivated Vaccines Market by Route of Administration
10.3.6.4 Japan Inactivated Vaccines Market
10.3.6.4.1 Japan Inactivated Vaccines Market by Type
10.3.6.4.2 Japan Inactivated Vaccines Market by Method
10.3.6.4.3 Japan Inactivated Vaccines Market by Route of Administration
10.3.6.5 South Korea Inactivated Vaccines Market
10.3.6.5.1 South Korea Inactivated Vaccines Market by Type
10.3.6.5.2 South Korea Inactivated Vaccines Market by Method
10.3.6.5.3 South Korea Inactivated Vaccines Market by Route of Administration
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Inactivated Vaccines Market Overview
10.4.2 Middle East and Africa Inactivated Vaccines Market Forecasts and Analysis
10.4.3 Middle East and Africa Inactivated Vaccines Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Inactivated Vaccines Market Forecasts and Analysis - By Method
10.4.5 Middle East and Africa Inactivated Vaccines Market Forecasts and Analysis - By Route of Administration
10.4.6 Middle East and Africa Inactivated Vaccines Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Inactivated Vaccines Market
10.4.6.1.1 South Africa Inactivated Vaccines Market by Type
10.4.6.1.2 South Africa Inactivated Vaccines Market by Method
10.4.6.1.3 South Africa Inactivated Vaccines Market by Route of Administration
10.4.6.2 Saudi Arabia Inactivated Vaccines Market
10.4.6.2.1 Saudi Arabia Inactivated Vaccines Market by Type
10.4.6.2.2 Saudi Arabia Inactivated Vaccines Market by Method
10.4.6.2.3 Saudi Arabia Inactivated Vaccines Market by Route of Administration
10.4.6.3 U.A.E Inactivated Vaccines Market
10.4.6.3.1 U.A.E Inactivated Vaccines Market by Type
10.4.6.3.2 U.A.E Inactivated Vaccines Market by Method
10.4.6.3.3 U.A.E Inactivated Vaccines Market by Route of Administration
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Inactivated Vaccines Market Overview
10.5.2 South and Central America Inactivated Vaccines Market Forecasts and Analysis
10.5.3 South and Central America Inactivated Vaccines Market Forecasts and Analysis - By Type
10.5.4 South and Central America Inactivated Vaccines Market Forecasts and Analysis - By Method
10.5.5 South and Central America Inactivated Vaccines Market Forecasts and Analysis - By Route of Administration
10.5.6 South and Central America Inactivated Vaccines Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Inactivated Vaccines Market
10.5.6.1.1 Brazil Inactivated Vaccines Market by Type
10.5.6.1.2 Brazil Inactivated Vaccines Market by Method
10.5.6.1.3 Brazil Inactivated Vaccines Market by Route of Administration
10.5.6.2 Argentina Inactivated Vaccines Market
10.5.6.2.1 Argentina Inactivated Vaccines Market by Type
10.5.6.2.2 Argentina Inactivated Vaccines Market by Method
10.5.6.2.3 Argentina Inactivated Vaccines Market by Route of Administration
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL INACTIVATED VACCINES MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of the World
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. INACTIVATED VACCINES MARKET, KEY COMPANY PROFILES
13.1. BHARAT BIOTECH
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CSL LTD.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. EMERGENT BIOSOLUTIONS
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. GLAXOSMITHKLINE PLC
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. MERCK AND CO., INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. NOVARTIS AG
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. PFIZER INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. SANOFI
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. SEQIRUS
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. VALNEVA SE
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Bharat Biotech
2. CSL Ltd.
3. Emergent BioSolutions
4. GlaxoSmithKline plc
5. Merck & Co., Inc.
6. Novartis AG
7. Pfizer Inc.
8. Sanofi
9. Seqirus
10. Valneva SE

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Life Sciences : READ MORE..